Journals, Peer Reviewers Cope with Surge in COVID-19 Publications

Coronavirus experts are swamped with reading submissions, which they’re working through as quickly as possible.

Written byClaire Jarvis
| 3 min read
coronavirus covid-19 sars-cov-2 peer review academic publishing scientific journals new england journal of medicine journal of virology

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: © ISTOCK.COM, ERHUI1979

Since the global pandemic of COVID-19 began, scientists and clinicians have rushed to understand and mitigate the threat, while sharing with other researchers what they know. Academic journals have already taken steps to accelerate the flow of peer-reviewed information by expediting editorial and peer review for coronavirus-related manuscripts and granting them open-access status upon publication.

“This coronavirus outbreak has led to a real surge on top of what we usually receive,” says Edward Campion, the executive editor of the New England Journal of Medicine (NEJM), who says the journal is receiving up to 40 coronarvirus-related submissions per day. He says the journal’s expert virologists “have been willing to review papers under very short turnarounds, sometimes less than 24 hours.”

I’m getting probably ten to twenty review requests a week. Before the outbreak, I was sticking to mostly four to six coronavirus papers per month.

Coronavirus experts ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • claire jarvis

    Claire Jarvis a science and medical writer based in Atlanta who contributes to The Scientist. With a research background in chemistry, she has covered the latest scientific and medical advances for Chemical & Engineering NewsChemistry WorldUndarkPhysics Today, and OneZero.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies